Business Context and Reporting Period
This Form 8-K was filed by Processa Pharmaceuticals, Inc. on May 20, 2021. The filing serves as a Regulation FD disclosure regarding the company's scheduled participation in the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain a financial statement or quarterly results summary.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing focuses solely on the announcement of an upcoming investor presentation.
Guidance, Outlook, and Management Commentary
- Upcoming Event: Management will present at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021.
- Disclosure Method: The presentation is furnished as Exhibit 99.1 and will be available on the company's website under the "Investors" section.
- Forward-Looking Statements: The company explicitly states it undertakes no duty or obligation to publicly update or revise the information contained in this report or the associated presentation.
- Regulation FD: The company notes it routinely uses its website to disclose material non-public information.
Investor Verification Checklist
- Verify the content of the May 2021 Corporate Presentation (Exhibit 99.1) for specific clinical or financial updates.
- Confirm the date and time of the virtual meetings at the Oppenheimer Rare & Orphan Disease Summit.
- Review the "Investors" section of processapharmaceuticals.com for the uploaded presentation materials.
- Note that the information in this 8-K is not deemed "filed" for purposes of Section 18 of the Exchange Act.